| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Flexicare is a privately owned, leading manufacturer and supplier of medical devices with over 40 years of experience in the healthcare sector. With over 40 years of experience in the design, development and manufacture of medical devices, Flexicare ha...
Minakem is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
United Drugs is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rocky Mountain CARES – HIV / AIDS Advocacy Group – Denver, Colorado